| Name | Title | Contact Details |
|---|
The Mundipharma story, spanning over six decades, is one that brings together a visionary approach and a pioneering spirit – and is best told through our patients, our employees and the communities in which we serve. Our dedication to putting patients at the heart of every business decision has ensured that we continue to grow and more importantly, improve the lives of the people who need our medicines the most. That foundation has not only delivered significant results, but is a reflection of our ability to convert entrepreneurism and innovation into business success. We are focused on the transformation of Mundipharma`s business in the important Emerging Markets – by leveraging our global leadership in pain and through a shared spirit of innovation, we are building a growing presence in antisepsis, respiratory, oncology, consumer healthcare and other specialty areas. Our unique approach to partnerships has given us the opportunity to establish a strong market presence that covers the world`s pharmaceutical markets. Today we are an innovative company, with more than 4,500 employees across the Emerging Markets and a distribution network covering six continents. And this is just the beginning of our story in this region.
Cingulate Therapeutics, LLC (CTx) is a privately held biopharmaceutical company focused on the development of new products for the treatment of central nervous system and neurobiological disorders.
Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.
Jamol Laboratories is a Emerson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.